abstract：:PBSCs are usually mobilized using G-CSF with or without chemotherapy. With the emergence of newer mobilizing agents, predicting poor mobilization may allow early intervention and prevent the costs and complications associated with remobilization. We retrospectively evaluated a cohort of 1556 patients seen between Janu...

journal_title：Bone marrow transplantation

authors： Sinha S,Gastineau D,Micallef I,Hogan W,Ansell S,Buadi F,Dingli D,Dispenzieri A,Gertz M,Greiner C,Hayman S,Inwards D,Johnston P,Lacy M,Litzow M,Porrata L,Winters JL,Kumar S

更新日期：2011-07-01 00:00:00

abstract：:In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

journal_title：Bone marrow transplantation

authors： Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

更新日期：2011-05-01 00:00:00

abstract：:Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a hi...

journal_title：Bone marrow transplantation

authors： Gatz SA,Benninghoff U,Schütz C,Schulz A,Hönig M,Pannicke U,Holzmann KH,Schwarz K,Friedrich W

更新日期：2011-04-01 00:00:00

abstract：:A nonmyeloablative conditioning regimen consisting of fludarabine (FLU) and 2 Gy TBI has been used extensively and with substantial engraftment success without promoting excessive nonrelapse mortality in medically infirm patients requiring hematopoietic cell transplantation. In this paper, we studied this same low-tox...

journal_title：Bone marrow transplantation

authors： Thakar MS,Kurre P,Storb R,Kletzel M,Frangoul H,Pulsipher MA,Leisenring W,Flowers ME,Sandmaier BM,Woolfrey A,Kiem HP

更新日期：2011-04-01 00:00:00

abstract：:Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, ...

journal_title：Bone marrow transplantation

authors： Rubin J,Vettenranta K,Vettenranta J,Bierings M,Abrahamsson J,Békássy AN,Håkansson Y,Frost BM,Arvidson J,Spendilow C,Winiarski J,Gustafsson B

更新日期：2011-03-01 00:00:00

abstract：:We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for ≥2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disea...

journal_title：Bone marrow transplantation

authors： Majhail NS,Bajorunaite R,Lazarus HM,Wang Z,Klein JP,Zhang MJ,Rizzo JD

更新日期：2011-03-01 00:00:00

abstract：:This study aimed to analyze the association between cytokine gene polymorphisms and outcome following allogeneic hematopoietic SCT (allo-HSCT). A total of 138 unrelated donor/recipient pairs who underwent allo-HSCT from 2001 to 2009 were tested for TNFA-1031 (T>C), -863 (C>A), -857 (C>T), -238 (G>A), TNFB+252 (A>G) an...

journal_title：Bone marrow transplantation

authors： Xiao HW,Lai XY,Luo Y,Shi JM,Tan YM,He JS,Xie WZ,Li L,Zhu XL,Zhu JJ,Sun J,Wei GQ,Jin L,Liu LZ,Wu KN,Yu XH,Cai Z,Lin MF,Ye XJ,Huang H

更新日期：2011-03-01 00:00:00

abstract：:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

journal_title：Bone marrow transplantation

authors： Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

更新日期：2011-02-01 00:00:00

abstract：:Six hundred and fifteen centers from 45 countries reported a total 30,293 HSCT to this 2008 EBMT survey with 26,810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphom...

journal_title：Bone marrow transplantation

authors： Gratwohl A,Baldomero H,Schwendener A,Gratwohl M,Apperley J,Frauendorfer K,Niederwieser D

更新日期：2011-02-01 00:00:00

abstract：:Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

journal_title：Bone marrow transplantation

authors： Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

更新日期：2011-01-01 00:00:00

abstract：:Autologous SCT (auto-SCT) introduces a reduced tolerance to chemotherapy even in patients with adequate engraftment, suggesting long-term effects of the transplantation procedure on the BM capacity. To study the hematopoietic cell compartment after auto-SCT, CD34(+) BM cells (n = 16) from patients at 6-9 months after ...

journal_title：Bone marrow transplantation

authors： Woolthuis C,Agool A,Olthof S,Slart RH,Huls G,Smid WM,Schuringa JJ,Vellenga E

更新日期：2011-01-01 00:00:00

abstract：:Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for autologous transplant in patients with lymphoma and multiple myeloma. In this study, we present the first European compassionate use experience in mobi...

journal_title：Bone marrow transplantation

authors： Duarte RF,Shaw BE,Marín P,Kottaridis P,Ortiz M,Morante C,Delgado J,Gayoso J,Goterriz R,Martínez-Chamorro C,Mateos-Mazón JJ,Ramírez C,de la Rubia J,Achtereekte H,Gandhi PJ,Douglas KW,Russell NH

更新日期：2011-01-01 00:00:00

abstract：:To control disease before allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory AML, we used clofarabine cytoreduction. Seventeen patients received clofarabine 30-40  mg/m(2) i.v. daily for 5 days with plans to initiate conditioning during the nadir, 14 days later. Bone marrow biopsy 12 days afte...

journal_title：Bone marrow transplantation

authors： Locke FL,Artz A,Rich E,Zhang Y,van Besien K,Stock W

更新日期：2010-12-01 00:00:00

abstract：:Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). PCR-based assays able to detect fungal DNA have been reported to precede clinical diagnosis of IFI. We performed a prospective study to evaluate a PCR-based pre-emptive approach. Ninety-nine patients undergoing reduced...

journal_title：Bone marrow transplantation

authors： Blennow O,Remberger M,Klingspor L,Omazic B,Fransson K,Ljungman P,Mattsson J,Ringdén O

更新日期：2010-12-01 00:00:00

abstract：:Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these disease...

journal_title：Bone marrow transplantation

authors： Godoi DF,Cardoso CR,Ferraz DB,Provinciatto PR,Cunha FQ,Silva JS,Voltarelli JC

更新日期：2010-10-01 00:00:00

abstract：:Acute GVHD has remained a significant cause of nonrelapse mortality after allogeneic hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning. The role of TNF-alpha in the biology of acute GVHD after nonmyeloablative conditioning has not been studied thus far. Here, we measured TNF receptor 1 (TNFR1...

journal_title：Bone marrow transplantation

authors： Willems E,Humblet-Baron S,Dengis O,Seidel L,Beguin Y,Baron F

更新日期：2010-09-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

journal_title：Bone marrow transplantation

authors： Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

更新日期：2010-08-01 00:00:00

abstract：:Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was st...

journal_title：Bone marrow transplantation

authors： Kanda Y,Yamashita T,Mori T,Ito T,Tajika K,Mori S,Sakura T,Hara M,Mitani K,Kurokawa M,Akashi K,Harada M

更新日期：2010-08-01 00:00:00

abstract：:We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-al...

journal_title：Bone marrow transplantation

authors： Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

更新日期：2010-07-01 00:00:00

abstract：:We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

journal_title：Bone marrow transplantation

authors： Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

更新日期：2010-06-01 00:00:00

abstract：:Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been s...

journal_title：Bone marrow transplantation

authors： Yang H,Robinson SN,Lu J,Decker WK,Xing D,Steiner D,Parmar S,Shah N,Champlin RE,Munsell M,Leen A,Bollard C,Simmons PJ,Shpall EJ

更新日期：2010-06-01 00:00:00

abstract：:Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. We assessed, from the perspective of the Spanish National Health Service, the cost-effectiveness of posaconazole vs fluconazole in preventing IFI. A ...

journal_title：Bone marrow transplantation

authors： de la Cámara R,Jarque I,Sanz MA,Grau S,Casado MA,Sabater FJ,Carreras E

更新日期：2010-05-01 00:00:00

abstract：:Immunological effects of IL-21 on T, B and natural killer (NK) cells have been reported, but the role of IL-21 in GVHD remains obscure. Here, we demonstrate that morbidity and mortality of GVHD was significantly reduced after BMT with splenocytes from IL-21R(-/-) mice compared with those from wild type mice. To furthe...

journal_title：Bone marrow transplantation

authors： Meguro A,Ozaki K,Oh I,Hatanaka K,Matsu H,Tatara R,Sato K,Leonard WJ,Ozawa K

更新日期：2010-04-01 00:00:00

abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

journal_title：Bone marrow transplantation

authors： Thompson JS,Chu Y,Glass JF,Brown SA

更新日期：2010-04-01 00:00:00

abstract：:We designed a phase I clinical trial of escalating doses of topotecan with CY and carboplatin in combination with autologous hematopoietic SCT (AHSCT) for the treatment of relapsed or persistent platinum sensitive ovarian or primary peritoneal carcinoma. After stem cell collection, 16 patients received topotecan at 1....

journal_title：Bone marrow transplantation

authors： Litzow MR,Peethambaram PP,Safgren SL,Keeney GL,Ansell SM,Dispenzieri A,Elliott MA,Gastineau DA,Gertz MA,Inwards DJ,Lacy MQ,Micallef IN,Porrata LF,Lingle WL,Hartmann LC,Frost MH,Barrette BA,Long HJ,Suman VJ,Reid JM,

更新日期：2010-03-01 00:00:00

abstract：:To assess the impact of CR on survival in multiple myeloma. Retrospective evaluation of response and survival among 758 consecutive patients with multiple myeloma treated at a single center, of whom 395 patients received intensive therapy supported by autologous stem cells within the first year. Survival times were ca...

journal_title：Bone marrow transplantation

authors： Wang M,Delasalle K,Feng L,Thomas S,Giralt S,Qazilbash M,Handy B,Lee JJ,Alexanian R

更新日期：2010-03-01 00:00:00

abstract：:Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

journal_title：Bone marrow transplantation

authors： Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

更新日期：2010-02-01 00:00:00

abstract：:Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple mye...

journal_title：Bone marrow transplantation

authors： Dugan MJ,Maziarz RT,Bensinger WI,Nademanee A,Liesveld J,Badel K,Dehner C,Gibney C,Bridger G,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:This was an open-label, single-center, phase II study of 20 patients with multiple myeloma who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT. The aim was to assess the safety and efficacy of plerixafor for stem cell mob...

journal_title：Bone marrow transplantation

authors： Tricot G,Cottler-Fox MH,Calandra G

更新日期：2010-01-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...

journal_title：Bone marrow transplantation

authors： Peres E,Levine JE,Khaled YA,Ibrahim RB,Braun TM,Krijanovski OI,Mineishi S,Abidi MH

更新日期：2010-01-01 00:00:00

abstract：:The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

journal_title：Bone marrow transplantation

authors： Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

更新日期：2010-01-01 00:00:00

abstract：:The Cleveland Clinic blood and marrow transplant program has routinely performed 'backup' autologous harvests in unrelated recipients with hematological malignancies in remission, lymphoma without marrow involvement and CML in chronic phase. We reviewed all adult or cord unrelated donor (URD) transplants performed fro...

journal_title：Bone marrow transplantation

authors： Stotler C,Bolwell B,Sobecks R,Dean R,Serafino S,Rybicki L,Andresen S,Pohlman B,Kalaycio M,Copelan E

更新日期：2010-01-01 00:00:00

abstract：:The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The comple...

journal_title：Bone marrow transplantation

authors： Paczesny S,Hanauer D,Sun Y,Reddy P

更新日期：2010-01-01 00:00:00

abstract：:The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobili...

journal_title：Bone marrow transplantation

authors： Ozcelik T,Topcuoglu P,Beksac M,Ozcan M,Arat M,Biyikli Z,Bakanay SM,Ilhan O,Gurman G,Arslan O,Demirer T

更新日期：2009-12-01 00:00:00

abstract：:Many factors, including lower risk of GVHD, rapid availability of 4/6-6/6 matched cord blood (CB) units and incremental gains in the outcomes, have led to an increasing use of CB transplantation (CBT) to treat many patients who lack fully matched adult BM donors. A large electronically searchable worldwide inventory o...

journal_title：Bone marrow transplantation

authors： Prasad VK,Kurtzberg J

更新日期：2009-11-01 00:00:00

abstract：:Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

journal_title：Bone marrow transplantation

authors： Freytes CO,Lazarus HM

更新日期：2009-11-01 00:00:00

abstract：:It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patien...

journal_title：Bone marrow transplantation

authors： Crowther M,Avenell A,Culligan DJ

更新日期：2009-10-01 00:00:00

abstract：:Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele and DRB1-DQB1 haplotyp...

journal_title：Bone marrow transplantation

authors： Hirv K,Bloch K,Fischer M,Einsiedler B,Schrezenmeier H,Mytilineos J

更新日期：2009-10-01 00:00:00

abstract：:The interaction between CXCL12 and its receptor CXCR4 plays a crucial role in the homing and mobilization of haematopoietic progenitors. We investigated the putative association between a CXCL12 gene polymorphism, the G --> A transition at position 801 in the 3'-untranslated region (3'UTR), and the yield of CD34(+) pr...

journal_title：Bone marrow transplantation

authors： Bogunia-Kubik K,Gieryng A,Dlubek D,Lange A

更新日期：2009-09-01 00:00:00

abstract：:SCT from an HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-t...

journal_title：Bone marrow transplantation

authors： Bregni M,Bernardi M,Servida P,Pescarollo A,Crocchiolo R,Treppiedi E,Corradini P,Ciceri F,Peccatori J

更新日期：2009-08-01 00:00:00